[The protective effect of trimetazidine on the myocardium against reperfusion injury during thrombolytic therapy of acute infarction].
Investigation of the protective action of the antiischemic drug trimetazidine (60 mg/kg) used during thrombolytic treatment of acute infarction showed that the drug effectively inhibits lipid peroxidation and reduces the degree of the reperfusive damage of myocardium, as determined from ECG (QRS index calculation) or from data on the blood creatinin phosphokinase level.
Rebrova
T Iu
TIu
Laboratory of Molecular-Cellular Pathology and Gene Diagnostics, Department of Emergency Cardiology, Institute of Cardiology, Tomsk Scientific Center, Siberian Division, Russian Academy of Medical Sciences, ul. Kievskaya 111, Tomsk, 634050 Russia.
Afanas'eva
S A
SA
Perchatkin
V A
VA
Maksimov
I V
IV
Markov
V A
VA
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism; D015912:Thrombolytic Therapy; D014292:Trimetazidine / Q000627:therapeutic use*
D014292:Trimetazidine